MCF-7 cell apoptosis and cell cycle arrest: Non-genomic effects of progesterone and mifepristone (RU-486)

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 4835-4840

  Fjelldal, Renathe ^a   Moe, Bjørn T ^a   Ørbo, Anne ^a   Sager, Georg ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Antiprogestins; Apoptosis; Breast cancer cells; Cell cycle; Cytotoxic; Mifepristone; Non genomic effects; Progestins

Indexed keywords

MIFEPRISTONE; PROGESTERONE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE ARREST; CELL DENSITY; CELL LEVEL; DRUG ACTIVITY; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

APOPTOSIS; BREAST NEOPLASMS; CELL COUNT; CELL CYCLE; CELL LINE, TUMOR; FEMALE; HUMANS; MIFEPRISTONE; PROGESTERONE; RECEPTORS, PROGESTERONE; UTERINE CERVICAL NEOPLASMS;

EID: 78751488034     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Alarid ET: Lives and times of nuclear receptors. Mol. Endocrinol 20: 1972-1981, 2006.
2. Cato AC, Nestl A and Mink S: Rapid actions of steroid receptors in cellular signaling pathways. Sci STKE, 2002.
3. Falkenstein E, Tillmann HC, Christ M, Feuring M and Wehling M: Multiple actions of steroid hormones - a focus on rapid, nongenomic effects. Pharmacol Rev 52: 513-556, 2000.
4. Leonhardt SA, Boonyaratanakornkit V and Edwards DP: Progesterone receptor transcription and non-transcription signaling mechanisms. Steroids 65: 761-770, 2003.
5. Boonyaratanakornkit V and Edwards DP: Receptor mechanisms mediating non-genomic actions of sex steroids. Semin Reprod Med 25: 139-153, 2007.
6. Gellersen B, Fernandes MS and Brosens JJ: Non-genomic progesterone actions in female reproduction. Hum Reprod Update 15: 119-138, 2009.
7. Vereide AB, Arnes M, Straume B, Maltau JM and Orbo A: Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 91: 526-533, 2003.
8. Orbo A, Rise CE and Mutter GL: Regression of latent endometrial precancers by progestin infiltrated intrauterine device. Cancer Res 66: 5613-5617, 2006. (Pubitemid 43927112)
9. Vereide AB, Kaino T, Sager G, Ames M and Orbo A: Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol Oncol 101: 214-223, 2006.
10. Orbo A, Jaeger R and Sager G: Serum modifies the concentration-dependent effects that sex steroids exert on cGMP and cAMP levels, and the growth of human C4-I cells (carcinoma of the uterine cervix). Int J Oncol 5: 619-625, 1994.
11. Sager G, Orbo A, Jaeger R and Engstrom C: Non-genomic effects of progestins-inhibition of cell growth and increased intracellular levels of cyclic nucleotides. J Steroid Biochem Mol. Biol 84: 1-8, 2003.
12. Berthelsen E, Endresen P, Orbo A and Sager G: Non-genomic cell growth inhibition by progesterone. Cell cycle retardation and induction of cell death. Anticancer Res 24: 3749-3756, 2004.
13. Leonhardt SA and Edwards DP: Mechanism of action of progesterone antagonists. Exp Biol Med 227: 969-980, 2002.
14. Moe BT, Vereide AB, Jæger R, Orbo A and Sager G: Levonorgestrel, medroxyprogesterone and progesterone cause a concentration-dependent reduction in endometrial cancer (Ishikawa) cell densities, and high concentrations of progesterone and mifepristone act in synergy. Anticancer Res 29: 1047-1052, 2009.
15. Dressing GE and Thomas P: Identification of membrane progestin receptors in human breast cancer cell lines and biopsies and their potential involvement in breast cancer. Steroids 72: 111-116, 2007.
16. Sadler SE and Mailer JL: Progesterone inhibits adenylate cyclase in xenopus oocytes. Action on the guanine nucleotide regulatory protein. J Biol Chem 256: 6368-6373, 1981. (Pubitemid 11058067)
17. Veselý DL and Hill DE: Estrogens and progesterone increase fetal and maternal guanylate cyclase activity. Endocrinology 107: 2104-2109, 1980.
18. Lange CA, Richer JK, Shen T and Horwitz KB: Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J Biol Chem 273: 31308-31316, 1998.
19. Luconi M, Krausz C, Barni T, Vannelli GB, Forti G and Baldi E: Progesterone stimulates p42 extracellular signal-regulated kinase (p42erk) in human spermatozoa. Mol. Hum Reprod 4: 251-258, 1998.
20. Horwitz KB, Costlow ME and McGuire WL: MCF-7; a human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors. Steroids 26: 785-795, 1975.
21. Berthois Y, Katzenellenbogen JA and Katzenellenbogen BS: Phenol red in tissue culture media is a weak estrogen: Implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci 83: 2496-2500, 1986.
22. Moe BT, Vereide AB, Orbo A and Sager G: Pharmacological concentrations of progesterone and mifepristone act in synergy to retard cell cycle and induce apoptosis of endometrial cancer (Ishikawa) cells. Anticancer Res 29: 1053-1058, 2009.
23. Darzynkiewicz Z, Bruno S, Del BG, Gorczyca W, Hotz MA, Lassota P and Tráganos F: Features of apoptotic cells measured by flow cytometry. Cytometry 13: 795-808, 1992.
24. Chou TC: Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 39: 253-276, 1976.
25. Schrader WT and O'Malley BW: Progesterone-binding components of chick oviduct. IV. Characterization of purified subunits. J Biol Chem 247: 51-59, 1972.
26. Maggi A, Schrader WT and O'Malley BW: Progesterone-binding sites of the chick oviduct receptor. Presence of a weaker ligand site which is destroyed by phosphatase treatment. J Biol Chem 259: 10956-10966, 1984.
27. Ashley RL, Arreguin-Arevalo JA and Nett TM: Binding characteristics of the ovine membrane progesterone receptor alpha and expression of the receptor during the estrous cycle. Reprod Biol Endocrinol 7, 2009.
28. Thomas P, Pang Y, Dong J, Groenen P, Kelder J, de Vlieg J, Zhu Y and Tubbs C: Steroid and G-protein binding characteristics of the seatrout and human progestin membrane receptor alpha subtypes and their evolutionary origins. Endocrinology 148: 705-718, 2007.
29. Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Mailer JL, Miller WT and Edwards DP: Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol. Cell 8: 269-280, 2001.
30. Luconi M, Marra F, Gandini L, Filimberti E, Lenzi A, Forti G and Baldi E: Phosphatidylinositol 3-kinase inhibition enhances human sperm motility. Hum Reprod 16: 1931-1937, 2001.
31. Yang CP, DePinho SG, Greenberger LM, Arceci RJ and Horwitz SB: Progesterone interacts with P-glycoprotein in multidrugresistant cells and in the endometrium of gravid uterus. J Biol Chem 264: 782-788, 1989.
32. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T and Hori R: Human P-glycoprotein transports Cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267: 24248-24252, 1992.
33. Mizutani T, Masuda M, Nakai E, Furumiya K, Togawa H, Nakamura Y, Kawai Y, Nakahira K, Shinkai S and Takahashi K: Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab 9: 167-174, 2008.
34. Sundkvist E, Jaeger R and Sager G: Pharmacological characterization of the ATP-dependent low K(m) guanosine 3',5'-cyclic monophosphate (cGMP) transporter in human erythrocytes. Biochem Pharmacol 63: 945-949, 2002. (Pubitemid 34243007)
35. Wielinga PR, van dH, I, Reid G, Beijnen JH, Wijnholds J and Borst P: Characterization of the MRP4-and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem 275: 17664-17671, 2003.
36. Andric SA, Kostic TS and Stojilkovic SS: Contribution of multidrug resistance protein MRP5 in control of cGMP intracellular signaling in anterior pituitary cells. Endocrinology 147: 3435-3445, 2006.
37. El Etreby MF, Liang Y, Wrenn RW and Schoenlein PV: Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat 51: 149-168, 1998. (Pubitemid 28561420)
38. Li DQ, Wang ZB, Bai J, Zhao J, Wang Y, Hu K and Du YH: Effects of mifepristone on proliferation of human gastric adenocarcinoma cell line SGC-7901 in vitro. World J Gastroenterol 10: 2628-2631, 2004. (Pubitemid 39214491)
39. Li A, Felix JC, Minoo P, Amezcua CA and Jain JK: Effect of mifepristone on proliferation and apoptosis of Ishikawa endometrial adenocarcinoma cells. Fértil Steril 84: 202-211, 2005.
40. Navo MA, Smith JA, Gaikwad A, Burke T, Brown J and Ramondetta LM: In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines. Cancer Chemother Pharmacol 62: 483-489, 2008.
41. Fardel O, Courtois A, Drenou B, Lamy T, Lecureur V, le Prise PY and Fauchet R: Inhibition of P-glycoprotein activity in human leukemic cells by mifepristone. Anticancer Drugs 7: 671-677, 1996.
42. Lecureur V, Fardel O and Guillouzo A: The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett 355: 187-191, 1994.
43. Johnstone RW, Ruefli AA, Tainton KM and Smyth MJ: A role for P-glycoprotein in regulating cell death. Leuk Lymphoma 35: 1-11, 2000.
44. Tainton KM, Smyth MJ, Jackson JT, Tanner JE, Cerruti L, Jane SM, Darcy PK and Johnstone RW: Mutational analysis of Pglycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ 11:1028-1037, 2004.
45. Amezcua CA, Lu JJ, Felix JC, Stanczyk FZ and Zheng W: Apoptosis may be an early event of progestin therapy for endometrial hyperplasia. Gynecol Oncol 79: 169-176, 2000.
46. Maruo T, Laoag-Fernandez JB, Pakarinen P, Murakoshi H, Spitz IM and Johansson E: Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium. Hum Reprod 16: 2103-2108, 2001.
47. Vereide AB, Kaino T, Sager G and Orbo A: Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high-dose gestagen therapy A comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 97: 740-750, 2005.
48. Sarkar NN: Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. Eur J Obstet Gynecol Reprod Biol 101: 113-120, 2002.